- Home
- ECAT vs BEAM Comparison
ECAT vs BEAM Comparison
Compare ECAT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECAT
- BEAM
- Stock Information
- Founded
- ECAT 2021
- BEAM 2017
- Country
- ECAT United States
- BEAM United States
- Employees
- ECAT N/A
- BEAM N/A
- Industry
- ECAT Trusts Except Educational Religious and Charitable
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ECAT Finance
- BEAM Health Care
- Exchange
- ECAT Nasdaq
- BEAM Nasdaq
- Market Cap
- ECAT 1.7B
- BEAM 1.7B
- IPO Year
- ECAT N/A
- BEAM 2020
- Fundamental
- Price
- ECAT $16.55
- BEAM $20.88
- Analyst Decision
- ECAT
- BEAM Strong Buy
- Analyst Count
- ECAT 0
- BEAM 10
- Target Price
- ECAT N/A
- BEAM $48.56
- AVG Volume (30 Days)
- ECAT 278.6K
- BEAM 2.8M
- Earning Date
- ECAT 01-01-0001
- BEAM 11-04-2025
- Dividend Yield
- ECAT 9.20%
- BEAM N/A
- EPS Growth
- ECAT N/A
- BEAM N/A
- EPS
- ECAT 2.39
- BEAM N/A
- Revenue
- ECAT N/A
- BEAM $60,272,000.00
- Revenue This Year
- ECAT N/A
- BEAM N/A
- Revenue Next Year
- ECAT N/A
- BEAM $17.95
- P/E Ratio
- ECAT $7.15
- BEAM N/A
- Revenue Growth
- ECAT N/A
- BEAM N/A
- 52 Week Low
- ECAT $14.02
- BEAM $13.53
- 52 Week High
- ECAT $17.30
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- ECAT 52.47
- BEAM 68.03
- Support Level
- ECAT $16.28
- BEAM $16.02
- Resistance Level
- ECAT $16.70
- BEAM $20.22
- Average True Range (ATR)
- ECAT 0.17
- BEAM 1.08
- MACD
- ECAT -0.02
- BEAM 0.46
- Stochastic Oscillator
- ECAT 62.13
- BEAM 99.25
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.